专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3167878B1 ALIPHATIC AMINE POLYMER SALTS FOR TABLETING 有权转让
公开(公告)号：EP3167878B1
公开(公告)日：2018-12-26
申请号：EP16199305.0
申请日：2005-11-01
申请人： Genzyme Corporation
发明人： BHAGAT, Hitesh , GOLDBERG, Jeffery Marc , HARIANAWALA, Abizer , BRENNER, Louis
IPC分类号： A61K9/20 , A61K31/13
CPC分类号： A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2866 , A61K31/13 , A61K31/785 , A61K47/02 , A61K47/34
摘要： The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37°C and at pH of at least 1 for a period of at least ten weeks at 60°C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.

3. 发明公开

EP3338767A1 CAPSULE COMPOSITIONS COMPRISING DONEPEZIL AND MEMANTINE 审中-公开
公开(公告)号：EP3338767A1
公开(公告)日：2018-06-27
申请号：EP17209510.1
申请日：2017-12-21
申请人： Sanovel Ilac Sanayi ve Ticaret A.S.
发明人： TÜRKYILMAZ, Ali , YILDIRIM, Ediz , MURATOGLU, Yesim
IPC分类号： A61K9/48 , A61K9/20 , A61K31/13 , A61K31/445 , A61K9/50
CPC分类号： A61K9/5084 , A61K9/2054 , A61K9/4808 , A61K31/13 , A61K31/445 , A61K2300/00
摘要： The present invention relates to a capsule dosage form comprising donepezil or a pharmaceutically acceptable salt thereof in combination with memantine or a pharmaceutically acceptable salt thereof.

4. 发明公开

EP3326617A1 ABUSE-DETERRENT DRUG FORMULATIONS 审中-公开
公开(公告)号：EP3326617A1
公开(公告)日：2018-05-30
申请号：EP17188009.9
申请日：2005-06-10
申请人： Collegium Pharmaceutical, Inc.
发明人： HIRSH, Jane. , FLEMING, Alison B. , RARIY, Roman V. , KLIBANOV, Alexander M.
IPC分类号： A61K9/14 , A61K9/20
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/145 , A61K9/148 , A61K9/1617 , A61K9/1664 , A61K9/2013 , A61K9/4808 , A61K9/4858 , A61K9/5015 , A61K9/5042 , A61K31/13 , A61K31/20 , A61K45/06 , A61K47/12 , A61K2300/00
摘要： An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

5. 发明公开

EP3151818A4 COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY 审中-公开
公开(公告)号：EP3151818A4
公开(公告)日：2018-05-30
申请号：EP15802805
申请日：2015-06-04
申请人： UNIV CASE WESTERN RESERVE
发明人： PALCZEWSKI KRZYSZTOF , KERN TIMOTHY
IPC分类号： A61K31/135 , A61K9/00 , A61K31/12 , A61K31/13 , A61K31/155 , A61K31/197 , A61K31/352 , A61K31/4164 , A61K31/4453 , A61K31/48 , A61K31/498 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/553 , A61K31/58 , A61K31/69 , A61K31/7076 , A61K33/24 , A61K45/06
CPC分类号： A61K33/24 , A61K9/0048 , A61K31/12 , A61K31/13 , A61K31/155 , A61K31/197 , A61K31/352 , A61K31/4164 , A61K31/4453 , A61K31/48 , A61K31/498 , A61K31/505 , A61K31/517 , A61K31/52 , A61K31/553 , A61K31/58 , A61K31/69 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要： A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by GPCR signaling pathways.

6. 发明公开

EP3322415A2 DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS ASSOCIATED WITH A NEURODEGENERATIVE DISEASE 审中-公开
公开(公告)号：EP3322415A2
公开(公告)日：2018-05-23
申请号：EP16825262.5
申请日：2016-07-15
申请人： Axovant Sciences GmbH , Friedhoff, Lawrence, T. , Ramaswamy, Shankar , Wen, Yandong
发明人： FRIEDHOFF, Lawrence Tim , RAMASWAMY, Shankar , WEN, Yandong
IPC分类号： A61K31/415 , C07D231/16 , C07C275/28
CPC分类号： A61K31/415 , A61K9/2018 , A61K31/13 , A61K31/135 , A61K31/198 , A61K31/27 , A61K31/4045 , A61K31/445 , A61K31/55 , A61K31/5513 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment and prophylaxis of visual hallucinations associated with Lewy Body dementia.

7. 发明公开

EP3193852A4 NMDA RECEPTOR ANTAGONISTS FOR TREATING GAUCHER DISEASE 审中-公开
公开(公告)号：EP3193852A4
公开(公告)日：2018-05-16
申请号：EP15840315
申请日：2015-09-10
申请人： YEDA RES & DEV
发明人： FUTERMAN ANTHONY , KLEIN ANDRES DAVID
IPC分类号： A61K31/13 , A61K9/00 , A61K31/439 , A61K49/00 , A61P25/00 , C12Q1/68 , C12Q1/6883 , G01N33/50
CPC分类号： A61K31/13 , A61K9/0019 , A61K31/439 , A61K49/0004 , C12Q1/6883 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/178 , G01N33/50 , G01N33/5058 , G01N2800/28 , G01N2800/2842
摘要： The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).

8. 发明公开

EP3182967A4 METHOD FOR TREATING HYPERHIDROSIS 有权
公开(公告)号：EP3182967A4
公开(公告)日：2018-04-04
申请号：EP15833912
申请日：2015-08-20
申请人： ATACAMA THERAPEUTICS INC
发明人： BENCHERIF MEROUANE
IPC分类号： A61K31/13 , A61K9/00 , A61K9/20 , A61P17/00
CPC分类号： A61K31/13 , A61K9/0053 , A61K9/20
摘要： The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis.

9. 发明公开

EP3299012A1 TRANSDERMAL LIQUID PREPARATION 审中-公开
标题翻译： TRANSDERMAL液体准备
公开(公告)号：EP3299012A1
公开(公告)日：2018-03-28
申请号：EP16796550.8
申请日：2016-05-19
申请人： MEDRx Co., Ltd.
发明人： YAMASAKI, Keiko
IPC分类号： A61K9/10 , A61K31/13 , A61K31/445 , A61K47/10 , A61K47/18 , A61K47/24 , A61P43/00
CPC分类号： A61K9/0014 , A61K9/10 , A61K31/13 , A61K31/135 , A61K31/4196 , A61K31/445 , A61K47/10 , A61K47/18 , A61K47/24
摘要： The present invention addresses the problem of providing a liquid preparation or external application, which has a shortened transdermal absorption lag time and has excellent transdermal absorption properties. The present invention also addresses the problem of providing a liquid preparation for external application, which is less irritative to skin. The problems can be solved by a transdermal liquid preparation comprising: (a) propylene glycol in an amount of 40 to 98% by weight; (b) phosphatidylcholine in an amount of 0.1 to 5% by weight; (c) oleyl alcohol and/or isostearyl alcohol in an amount of 0.1 to 10% by weight; and (d) a medicine in an amount of 0.1 to 25% by weight. It is preferred that the transdermal liquid preparation additionally contains an alkanol amine. The alkanol amine is preferably triethanolamine.
摘要翻译：本发明解决了提供液体制剂或外用药物的问题，其具有缩短的经皮吸收滞后时间并具有优异的透皮吸收性质。本发明还解决了提供对皮肤刺激性较小的外用液体制剂的问题。这些问题可以通过透皮液体制剂来解决，所述透皮液体制剂包含：（a）40-98重量％的丙二醇; （b）0.1至5重量％的磷脂酰胆碱; （c）0.1-10重量％的油醇和/或异硬脂醇; 和（d）0.1至25重量％的药物。优选透皮液体制剂另外含有链烷醇胺。链烷醇胺优选三乙醇胺。

10. 发明公开

EP3291816A1 COMPOSITIONS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE 审中-公开
标题翻译：治疗神经退行性疾病的组合物和方法
公开(公告)号：EP3291816A1
公开(公告)日：2018-03-14
申请号：EP16790213.9
申请日：2016-05-06
申请人： Axovant Sciences GmbH , Friedhoff, Lawrence, T. , Kishnani, Kunal , Lewis, Bryan M. , Piscitelli, Stephen Clement , Ramaswamy, Geetha , Ramaswamy, Shankar , Rhodes, Melissa
发明人： FRIEDHOFF, Lawrence Tim , KISHNANI, Kunal , LEWIS, Bryan M. , PISCITELLI, Stephen Clement , RAMASWAMY, Geetha , RAMASWAMY, Shankar , RHODES, Melissa
IPC分类号： A61K31/496 , A61K31/497 , A61P25/28
CPC分类号： A61K45/06 , A61K9/0053 , A61K9/2054 , A61K9/209 , A61K31/13 , A61K31/27 , A61K31/415 , A61K31/445 , A61K31/4709 , A61K31/55 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/28 , A61K2300/00
摘要： The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式